Antigen neutralizing capacity, pharmacokinetics (plasma retention), immunogenicity, safety better than TOCILIZUMAB by combining appropriate modification of the CDR region amino acid sequences, modification of the variable region amino acid sequence, a modification of the constant region amino acid sequence , rheumatoid arthritis as an active ingredient an anti-IL-6 receptor antibody properties have been improved, I was successful in the creation of a therapeutic agent for Castlemans disease or pediatric chronic arthritis.CDR領域アミノ酸配列の改変、可変領域アミノ酸配列の改変、定常領域アミノ酸配列の改変を適切に組み合わせることでTOCILIZUMABより優れた抗原中和能、薬物動態(血漿中滞留性)、免疫原性、安全性、物性が改善された抗IL-6受容体抗体を有効成分とする関節リウマチ、小児慢性関節炎またはキャッスルマン病の治療剤の創製に成功した。
